HK1243713A1 - 一種化合物的固體形式及其使用方法 - Google Patents

一種化合物的固體形式及其使用方法

Info

Publication number
HK1243713A1
HK1243713A1 HK18103068.1A HK18103068A HK1243713A1 HK 1243713 A1 HK1243713 A1 HK 1243713A1 HK 18103068 A HK18103068 A HK 18103068A HK 1243713 A1 HK1243713 A1 HK 1243713A1
Authority
HK
Hong Kong
Prior art keywords
compound
methods
solid forms
solid
forms
Prior art date
Application number
HK18103068.1A
Other languages
English (en)
Inventor
Margaret De Paul Susan
Perlberg Anett
Mangzhu Zhao Matthew
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of HK1243713A1 publication Critical patent/HK1243713A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/14Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals
HK18103068.1A 2008-07-17 2018-03-02 一種化合物的固體形式及其使用方法 HK1243713A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17

Publications (1)

Publication Number Publication Date
HK1243713A1 true HK1243713A1 (zh) 2018-07-20

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103068.1A HK1243713A1 (zh) 2008-07-17 2018-03-02 一種化合物的固體形式及其使用方法

Country Status (29)

Country Link
US (2) US8217156B2 (zh)
EP (1) EP2332947B1 (zh)
JP (2) JP2011528366A (zh)
KR (2) KR101707246B1 (zh)
CN (2) CN107629097A (zh)
AR (1) AR072807A1 (zh)
AU (1) AU2009270973B2 (zh)
BR (1) BRPI0916191A2 (zh)
CA (1) CA2730931A1 (zh)
CL (1) CL2009001595A1 (zh)
CO (1) CO6351797A2 (zh)
DK (1) DK2332947T3 (zh)
ES (1) ES2656357T3 (zh)
HK (1) HK1243713A1 (zh)
HU (1) HUE035400T2 (zh)
IL (1) IL210269A (zh)
MX (1) MX2011000503A (zh)
NO (1) NO2332947T3 (zh)
NZ (1) NZ590184A (zh)
PE (1) PE20100260A1 (zh)
PL (1) PL2332947T3 (zh)
PT (1) PT2332947T (zh)
RU (1) RU2505543C2 (zh)
SG (1) SG185317A1 (zh)
TW (1) TWI472521B (zh)
UA (1) UA106048C2 (zh)
UY (1) UY31992A (zh)
WO (1) WO2010009197A1 (zh)
ZA (1) ZA201100175B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
NZ582536A (en) 2007-07-26 2012-01-12 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
NZ707859A (en) 2012-11-20 2019-03-29 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose cotransporter 1
EP3057970A1 (en) 2013-10-18 2016-08-24 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
SG11201800510WA (en) 2015-07-30 2018-02-27 Microbial Chem Res Found New effective aminoglycoside antibiotic for multidrug-resistant bacteria
JP6727419B2 (ja) * 2016-05-25 2020-07-22 クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
BR112021004839A2 (pt) * 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
KR20220030930A (ko) * 2019-07-05 2022-03-11 산동 단홍 파머수티컬 컴퍼니., 리미티드. SGLTs 억제제의 결정형 및 그 응용
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
EP3771718A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
US20240100013A1 (en) 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
WO2022155303A1 (en) 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
NZ582536A (en) * 2007-07-26 2012-01-12 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
BRPI0916191A2 (pt) 2017-08-29
AU2009270973B2 (en) 2014-01-30
US20130165395A1 (en) 2013-06-27
AU2009270973A1 (en) 2010-01-21
CL2009001595A1 (es) 2010-07-19
UA106048C2 (uk) 2014-07-25
EP2332947A1 (en) 2011-06-15
PE20100260A1 (es) 2010-04-16
IL210269A0 (en) 2011-03-31
CA2730931A1 (en) 2010-01-21
KR20170010069A (ko) 2017-01-25
RU2011105797A (ru) 2012-08-27
HUE035400T2 (en) 2018-05-02
NO2332947T3 (zh) 2018-03-31
NZ590184A (en) 2012-09-28
AR072807A1 (es) 2010-09-22
KR101707246B1 (ko) 2017-02-15
TWI472521B (zh) 2015-02-11
MX2011000503A (es) 2011-03-01
JP2016041701A (ja) 2016-03-31
IL210269A (en) 2015-06-30
CN102112483A (zh) 2011-06-29
RU2505543C2 (ru) 2014-01-27
CN107629097A (zh) 2018-01-26
EP2332947B1 (en) 2017-11-01
JP6283337B2 (ja) 2018-02-21
ES2656357T3 (es) 2018-02-26
ZA201100175B (en) 2012-03-28
US8217156B2 (en) 2012-07-10
US9067962B2 (en) 2015-06-30
JP2011528366A (ja) 2011-11-17
PT2332947T (pt) 2018-02-06
WO2010009197A1 (en) 2010-01-21
KR20110031196A (ko) 2011-03-24
CO6351797A2 (es) 2011-12-20
PL2332947T3 (pl) 2018-04-30
US20100016422A1 (en) 2010-01-21
SG185317A1 (en) 2012-11-29
UY31992A (es) 2010-02-26
DK2332947T3 (da) 2018-01-29
TW201006808A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
HK1243713A1 (zh) 一種化合物的固體形式及其使用方法
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
EG27167A (en) Microemulsifiers and methods of making and using same
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
GB0818241D0 (en) Compounds and their use
IL208081A0 (en) Amido - thiophene compounds and their use
HK1149933A1 (zh) 二氮咔唑和其使用方法
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201007395B (en) Aryl-quinolyl compounds and their use
IL209548A0 (en) Diazacarbazoles and methods of use
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL206125A0 (en) Azaindolizines and methods of use
PL2344449T3 (pl) Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie
ZA201205075B (en) Fungicidal compound and method of their use
HK1160925A1 (zh) 組織蛋白酶 的用途
IL213695A0 (en) Adhesive compounds and methods of use thereof
GB0922510D0 (en) Compound and use
EP2470022A4 (en) COMPOUNDS AND METHODS
GB0801319D0 (en) Compounds and their use
GB0903348D0 (en) Compounds and methods relating thereto
GB0809975D0 (en) A multi-optic rule and method of use
GB0821348D0 (en) Compounds and preparation methods
HU0800656D0 (en) Effective use of tea-composition
GB0802194D0 (en) Compounds and their use